Protease-activated receptors in kidney disease progression

被引:38
|
作者
Palygin, Oleg [1 ]
Ilatovskaya, Daria V. [1 ]
Staruschenko, Alexander [1 ]
机构
[1] Med Coll Wisconsin, Dept Physiol, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA
基金
美国国家卫生研究院;
关键词
serine proteases; perivascular cells; calcium transient; chronic kidney disease; THROMBIN RECEPTOR; EXPRESSION; PAR-2; RESPONSES; INFLAMMATION; KALLIKREINS; MECHANISMS; GENERATION; INHIBITION; SECRETION;
D O I
10.1152/ajprenal.00460.2016
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Proteaseactivated receptors (PARs) are members of a well-known family of transmembrane G protein-coupled receptors (GPCRs). Four PARs have been identified to date, of which PAR1 and PAR2 are the most abundant receptors, and have been shown to be expressed in the kidney vascular and tubular cells. PAR signaling is mediated by an N-terminus tethered ligand that can be unmasked by serine protease cleavage. The receptors are activated by endogenous serine proteases, such as thrombin (acts on PARs 1, 3, and 4) and trypsin (PAR2). PARs can be involved in glomerular, microvascular, and inflammatory regulation of renal function in both normal and pathological conditions. As an example, it was shown that human glomerular epithelial and mesangial cells express PARs, and these receptors are involved in the pathogenesis of crescentic glomerulonephritis, glomerular fibrin deposition, and macrophage infiltration. Activation of these receptors in the kidney also modulates renal hemodynamics and glomerular filtration rate. Clinical studies further demonstrated that the concentration of urinary thrombin is associated with glomerulonephritis and type 2 diabetic nephropathy; thus, molecular and functional mechanisms of PARs activation can be directly involved in renal disease progression. We briefly discuss here the recent literature related to activation of PAR signaling in glomeruli and the kidney in general and provide some examples of PAR1 signaling in glomeruli podocytes.
引用
收藏
页码:F1140 / F1144
页数:5
相关论文
共 50 条
  • [1] PROTEASE-ACTIVATED RECEPTORS IN HEALTH AND DISEASE
    Peach, Chloe J.
    Edgington-Mitchell, Laura E.
    Bunnett, Nigel W.
    Schmidt, Brian L.
    [J]. PHYSIOLOGICAL REVIEWS, 2023, 103 (01) : 717 - 785
  • [2] Protease-activated receptors
    Coughlin, SR
    [J]. FASEB JOURNAL, 2001, 15 (04): : A22 - A22
  • [3] Protease-activated receptors
    Bahou, WF
    [J]. CELL SURFACE PROTEASES, 2003, 54 : 343 - 369
  • [4] Protease-activated receptors: Contribution to physiology and disease
    Ossovskaya, VS
    Bunnett, NW
    [J]. PHYSIOLOGICAL REVIEWS, 2004, 84 (02) : 579 - 621
  • [5] Protease-activated receptors and neuroplasticity: Protease-activated receptors as a possible target for cathepsin B
    Davydova, O. N.
    Yakovlev, A. A.
    [J]. NEUROCHEMICAL JOURNAL, 2010, 4 (01) : 1 - 7
  • [6] Protease-activated receptors and neuroplasticity: Protease-activated receptors as a possible target for cathepsin B
    O. N. Davydova
    A. A. Yakovlev
    [J]. Neurochemical Journal, 2010, 4 : 1 - 7
  • [7] Protease-activated receptors and inflammation
    Vergnolle, Nathalie
    [J]. ACTA PHARMACOLOGICA SINICA, 2006, 27 : 11 - 11
  • [8] Protease-activated receptors in hemostasis
    Nieman, Marvin T.
    [J]. BLOOD, 2016, 128 (02) : 169 - 177
  • [9] Protease-activated receptors and prostaglandins in inflammatory lung disease
    Peters, Terence
    Henry, Peter J.
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2009, 158 (04) : 1017 - 1033
  • [10] Protease-Activated Receptors - Key Regulators of Inflammatory Bowel Diseases Progression
    Jacenik, Damian
    Fichna, Jakub
    Malecka-Wojciesko, Ewa
    Mokrowiecka, Anna
    [J]. JOURNAL OF INFLAMMATION RESEARCH, 2021, 14 : 7487 - 7497